Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26596670

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Dec
First author
Gay F

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Dec;16(16):1571-3. doi: 10.1016/S1470-2045(15)00457-X.
    note
    Source null
    related pmid
    26596669
    relationship
    Comment in

Authors and identifiers

  1. name
    Gay F
    type
    Author
  2. name
    Oliva S
    type
    Author
  3. name
    Petrucci MT
    type
    Author
  4. name
    Conticello C
    type
    Author
  5. name
    Catalano L
    type
    Author
  6. name
    Corradini P
    type
    Author
  7. name
    Siniscalchi A
    type
    Author
  8. name
    Magarotto V
    type
    Author
  9. name
    Pour L
    type
    Author
  10. name
    Carella A
    type
    Author
  11. name
    Malfitano A
    type
    Author
  12. name
    Petrò D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gay F
    type
    Author
  2. name
    Oliva S
    type
    Author
  3. name
    Petrucci MT
    type
    Author
  4. name
    Conticello C
    type
    Author
  5. name
    Catalano L
    type
    Author
  6. name
    Corradini P
    type
    Author
  7. name
    Siniscalchi A
    type
    Author
  8. name
    Magarotto V
    type
    Author
  9. name
    Pour L
    type
    Author
  10. name
    Carella A
    type
    Author
  11. name
    Malfitano A
    type
    Author
  12. name
    Petrò D
    type
    Author
bibliography ids
  1. nci-bib-2e380e0efe20c84f4a42ef78
book metadata
content sha256
587366078691a1c12f5a353ccde056be9e2172821f1eeb30361b44e0dab77ece
document type
citation
dois
  1. 10.1016/S1470-2045(15)00389-7
electronic publication date
display
2015 Nov 17
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26596670
immutable id
pubmed:26596670@587366078691a1c12f5a353ccde056be9e2172821f1eeb30361b44e0dab77ece
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
16
name
The Lancet. Oncology
nlm unique id
100957246
pages
1617-29
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Dec;16(16):1571-3. doi: 10.1016/S1470-2045(15)00457-X.
    note
    Source null
    related pmid
    26596669
    relationship
    Comment in
outcomes validated
false
pmid
26596670
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
824672266b74333d03988855be7fe2249875b5cacb0097127ddfaab2885f546d
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2015 Dec
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26596670/
title
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Preserved source evidence · Not medical advice